Atacicept for IgA Nephropathy: ORIGIN Phase 2b Clinical Trial Week 36 Results

Atacicept is a potential best-in-class, disease-modifying dual inhibitor of the cytokines B cell activating factor (BAFF, also known as B lymphocyte stimulator or BLyS) and A proliferation-inducing ligand (APRIL). In the ORIGIN Phase 2b clinical trial in IgA nephropathy, atacicept met its primary and key secondary endpoints. Learn more at veratx.com.